Ozempic Nation: How Weight-Loss Drugs Are Rewriting Consumer Marketing
With roughly one in eight US adults having tried a GLP-1 drug and Bain estimating billions already cut from grocery and fast-food spending, the appetite-suppressant boom has become a slow-motion demand shock that food, drink and retail brands must now actively market around.
A quiet demand shock
The GLP-1 story is usually told as pharma or health news. For marketers it is a demand story, and a profound one. When a meaningful slice of the population simply wants to eat less — smaller portions, fewer snacks, less alcohol, less ultra-processed food — the effect ripples through every category built on indulgence and volume. Bain and others have already pointed to billions trimmed from grocery and fast-food spending, and the arrival of cheaper pill forms could widen the effect considerably.
This is not a diet trend that fades by March. It is a structural change in how much, and what, a growing cohort of consumers wants to consume. Campbell's reworking its marketing amid layoffs is the kind of adjustment legacy food brands will keep making.
Winners, losers and the reframe in between
The naive read is 'indulgence loses, health wins'. The real picture is more interesting. Volume-dependent, large-portion, high-snack categories face genuine pressure. But GLP-1 users still eat — they just want protein density, smaller premium portions, and food that feels like a treat without the volume. That is a gift to brands that can reframe around quality-per-bite rather than quantity.
Marketing Minute's framework is to stop marketing volume and start marketing value-per-calorie. 'More' was the oldest promotion in the food business — bigger bag, meal deal, bottomless refill. For a shrinking-appetite consumer, 'more' is now a reason not to buy. The pivot is toward premium small formats, high-protein positioning, and permission-to-enjoy messaging that makes a smaller indulgence feel intentional rather than restrictive.
The practical playbook
Three moves matter now. Reformat: test smaller, premium pack sizes before your category is forced into them. Reframe: lead on satisfaction and quality, not size and saving. And re-segment: the GLP-1 cohort skews higher-income and brand-loyal, so treat them as a premium audience to court, not a lost volume to mourn.
For SMEs in food and drink, this is a rare moment where being small is an advantage — you can change a format or a message in weeks while a multinational needs a year. The brands that win the next three years will be the ones that noticed their best customers were quietly eating less, and built for it before the sales data forced them to.
Quick FAQ
Will GLP-1 drugs really dent food and drink sales?
The early evidence says yes at the margin — Bain and others estimate billions already trimmed from grocery and fast-food spending — with the biggest pressure on high-volume, high-snack, indulgence categories.
How should brands respond?
Shift from marketing volume to marketing value-per-bite: premium smaller formats, protein and satisfaction messaging, and treating GLP-1 users as a high-value premium segment rather than lost volume.
'More' used to be the most powerful word in food marketing — bigger bag, bottomless refill, meal deal. For a customer on a GLP-1, 'more' is a reason to walk away. The brands that win will stop selling quantity and start selling quality per bite. — Daniel Nikolla, Founder of Merx Marketing
Stop marketing volume. A shrinking-appetite consumer buys satisfaction-per-bite — reformat, reframe and court them as a premium segment.
If your best customers suddenly wanted to consume a third less, would your marketing still make sense?
If you would like to know more about this topic, please contact us on danieln@merxmarketing.co.uk
Sources: Bain & Company; KFF; Supermarket News; Marketing Minute analysis.
Related reading
Written by Daniel Nikolla, Founder of Merx Marketing Ltd and Marketing Minute
